U.S. flag An official website of the United States government
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Investigational New Drug Applications (INDs) - Determining Whether Human Research Studies Can Be Conducted Without an IND
  1. Regulatory Information

GUIDANCE DOCUMENT

Investigational New Drug Applications (INDs) - Determining Whether Human Research Studies Can Be Conducted Without an IND Guidance for Clinical Investigators, Sponsors, and IRBs September 2013

Final

Investigational New Drug Applications (INDs) - Determining Whether Human Research Studies Can Be Conducted Without an IND

Issued by:
Guidance Issuing Office
Center for Food Safety and Applied Nutrition
Center for Drug Evaluation and Research
Center for Biologics Evaluation and Research

This guidance is intended to assist clinical investigators, sponsors, sponsor-investigators,2 and institutional review boards (IRBs) in determining whether research studies involving human subjects must be conducted under an investigational new drug application (IND), as described in title 21 of the Code of Federal Regulations, part 312 (21 CFR part 312) (the IND regulations). This guidance describes when an IND is required, specific situations in which an IND is not required, and a range of issues that, in FDA’s experience, have been the source of confusion or misperceptions about the application of the IND regulations.3 This guidance addresses only whether an IND is needed. If your study also involves the use of a device, you should determine whether such use is subject to 21 CFR part 812 (the IDE regulations).


Submit Comments

Submit comments on this guidance document electronically via docket ID: FDA-2013-S-0610 - Specific Electronic Submissions Intended For FDA's Dockets Management Staff (i.e., Citizen Petitions, Draft Proposed Guidance Documents, Variances, and other administrative record submissions)

If unable to submit comments online, please mail written comments to:

Division of Dockets Management (HFA- 305)
Food and Drug Administration
5630 Fishers Lane, Rm. 1061
Rockville, MD 20852

All comments should be identified with the title of the guidance.